Tocilizumab, a rheumatoid arthritis treatment, delivers encouraging results in combating cytokine storms—a key factor in COVID-19 patient fatalities—according to Assistance Publique-Hôpitaux de Paris (AP-HP).
SARS-CoV-2 invasion of the lungs sparks a robust immune response. The body mobilizes millions of cells, including cytokines, to battle the virus and repair lung tissue.
Typically, this inflammation targets infected areas precisely. However, aggressive viruses can overwhelm the system, leading to excessive cytokine production. This attacks both infected and healthy tissues, a phenomenon known as a "cytokine storm" observed in severe COVID-19 cases.
As virologist Angela Rasmussen from Columbia University's Mailman School of Public Health explains to National Geographic: "Instead of aiming at a target with a rifle, it's like using a missile." This overreaction worsens outcomes rather than aiding recovery.
Global labs are racing to develop immunomodulators to tame these runaway reactions.
AP-HP's CORIMUNO-19 trial, launched April 3, enrolled 129 patients with moderate-to-severe pneumonia across 13 hospitals, all needing oxygen support.
Of these, 65 received one or two doses of tocilizumab (from Roche) alongside standard care (oxygen, antibiotics, anticoagulants); the rest got standard care only. All were monitored for 14 days.
A preliminary report on April 27 highlighted encouraging outcomes: tocilizumab "significantly improved prognosis," per AP-HP's press release.
By blocking the interleukin-6 receptor, the drug shows potential to prevent cytokine storms in COVID-19.
France's Ministry of Health noted: "Patients on tocilizumab needed less ventilation support and had lower mortality rates over 14 days. This is the first drug demonstrating a significant effect in a clinical trial."
Results await peer review, with full publication expected soon. Doctors shared early findings ethically while continuing long-term follow-up, AP-HP stated.
Source
